ATHENA (A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)
ATHENA (A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)
This is a Phase 3, randomized, multinational, double-blind, dual placebo-controlled, 4-arm study evaluating rucaparib and nivolumab as maintenance treatment following response to front-line treatment in newly diagnosed ovarian cancer patients. Response to treatment will be analyzed based on homologous recombination (HR) status of tumor samples.
Inclusion Criteria:
Exclusion Criteria:
Saint Louis Park, Minnesota 55416, United States
Saint Leonards, New South Wales 2065, Australia
Sherbrooke, Quebec J1H 5N4, Canada
Prague, Czechia
Ota-shi, Gunma 373-8550, Japan
Naka, Hiroshima 730-0844,, Japan
Kawasaki-shi, Kanagawa 211-8533, Japan
Shinjuku-Ku, Shinanomachi, Japan
Koto-Ku, Tokyo, Japan
Warsaw, Kondratowicza, Poland
Pesochnyy, 197758, Russia
Saint Petersburg, 198255, Russia
Saransk, 430032, Russia
Sochi, 354057, Russia
Incheon, Seoul 21565, South Korea
Ankara, Turkey (Türkiye)
Canterbury, Kent CT1 3NG, United Kingdom